BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Seegene Advances Comprehensive HPV and STI PCR Testing with Large-Scale Clinical Evidence

STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive case...

July 29, 2026 | News

Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line

One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...

July 28, 2026 | Analysis

OrbusNeich Enrols First Patient in Pivotal Japanese Trial of Coronary Drug-Coated Balloon

OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device comp...

July 28, 2026 | News

AnHorn Medicines Advances First-in-Class AH-008 into Phase I Trial for Chemotherapy-Induced Neuropathy Prevention

AnHorn Medicines announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotect...

July 27, 2026 | News

Harbour BioMed Forecasts Record H1 2026 Profit as Strategic Partnerships Drive Growth

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutic...

July 27, 2026 | Company results

ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...

July 27, 2026 | News

Laminar Pharma Completes Pivotal Phase 2b/3 Trial of LAM561 in Newly Diagnosed Glioblastoma

Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, announced that the last patient has c...

July 27, 2026 | News

Ribo’s Vortosiran Achieves 92% FXI Activity Reduction in Phase 2a Coronary Artery Disease Study

Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at C...

July 24, 2026 | News

Alebund Doses First Participant in Global Phase IIb Trial of AP306 for Hyperphosphatemia

Alebund Pharmaceuticals a renal-focused biopharmaceutical company, announced that the first participant has been randomized and dosed in the global Phase I...

July 23, 2026 | News

Lundbeck Completes Patient Randomisation in Phase III Bexicaserin Trial for Rare Epilepsies

DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse ...

July 22, 2026 | News

China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer

SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...

July 21, 2026 | News

Dimerix Acquires Phase II-Ready DMX-652 to Expand Kidney Disease Pipeline

Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New D...

July 20, 2026 | News

Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...

July 20, 2026 | News

Telix Advances Illuccix Towards Japan Approval After Completing Phase III Patient Enrollment

Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data wil...

July 20, 2026 | News

Stay Connected